Pairing Radiation Oncology and Palliative Care Leads to Better Outcomes

Article

A novel service model allowed for shorter durations of treatment with radiation, fewer unfinished treatments with radiation, shorter hospital stays and increased use of palliative care.

An intervention combining palliative care with radiation oncology led to better results among patients with painful bone metastases, according to preliminary findings from a new study. These results will be presented at the 2015 Palliative Care in Oncology Symposium from October 9-10.

The novel service model allowed for shorter durations of treatment with radiation, fewer unfinished treatments with radiation, shorter hospital stays and increased use of palliative care.

“Our study validates the importance of cohesive collaboration in cancer care. As a palliative radiation oncologist, tackling pain is only a small part of what I do,” Kavita Dharmarajan, MD, MSc, the study’s senior author, said in a statement. “My role extends to engage patients and families in conversations that help distill their priorities and set realistic expectations of treatment.”

“Partnering with palliative care helps us incorporate goals and preferences into our care plans.”

The standard treatment for bone metastases is 10 radiation treatments, says Dharmarajan, an assistant professor of radiation oncology and palliative medicine at Mount Sinai Medical Center. Occasionally, Dharmarajan noted, patients do not survive long enough following radiation to experience its benefits. Shorter treatment is as effective but is currently underutilized.

The novel service model called for increased use of single-fraction radiation treatment (given in a single session) and fraction radiation treatments given over the course of one week or less. In the study, patients receiving five or fewer radiation treatments increased from 26 to 61 percent.

In total, 336 patients with stage 4 cancer receiving radiation treatment for bone metastases were evaluated. From December 2010 to September 2013, 175 patients received standard care and from October 2013 to September 2015, 161 patients received care under the new model.

Use of shorter radiation treatments under the new model was associated with an increase in the proportion of patients receiving palliative care within a month (49 versus 34 percent). The new model also led to a decrease in patients’ median length of stay (18 versus 12 days) and a reduction in the proportion of unfinished radiation treatments (15 versus 8 percent).

“This is important work and it demonstrates first-hand the practical impact incorporating palliative care can have to standard treatment,” said Don S. Dizon, MD, clinical co-director, Gynecologic Oncology, Massachusetts General Hospital, and ASCO expert, during the presscast.

Crucially, changes in care under the new model did not affect the ability to relieve pain — 80 percent of patients achieved pain relief under the new model compared with 74 percent under the old model, though the difference was not statistically significant.

“It’s possible not only to tailor our treatment for patients with bone metastases, leading to better utilization of resources and higher completions of therapy, but we can do so without negatively impacting the goals of treatment in the first place,” Dizon said.

During the presscast, Dharmarajan told the story of “Mrs. Jones,” a 48-year-old patient with advanced breast cancer who was admitted with severe back pain from metastases to her spine. As the mother of two teenage boys, her goals were to spend as much time with them as possible and live as long as possible.

Had she received care by the palliative/radiation intervention, Dharmarajan says, Jones would have been most likely referred to palliative care services, her pain would have most likely been controlled and she would have been able to spend six more days at home with her sons.

“When we work together, patients receive a higher quality of care that focuses on the whole person, not just a tumor,” Dharmarajan said.

Chang S, Smith CB, Morrison S, et al. A palliative radiation oncology consult service’s impact on care of advanced cancer patients with symptomatic bone metastases. J Clin Oncol. 2015;33(suppl; abstr 110).

Related Videos
For patients with cancer, the ongoing chemotherapy shortage may cause some anxiety as they wonder how they will receive their drugs. However, measuring drugs “down to the minutiae of the milligrams” helped patients receive the drugs they needed, said Alison Tray. Tray is an advanced oncology certified nurse practitioner and current vice president of ambulatory operations at Rutgers Cancer Institute in New Jersey.  If patients are concerned about getting their cancer drugs, Tray noted that having “an open conversation” between patients and providers is key.  “As a provider and a nurse myself, having that conversation, that reassurance and sharing the information is a two-way conversation,” she said. “So just knowing that we're taking care of you, we're going to make sure that you receive the care that you need is the key takeaway.” In June 2023, many patients were unable to receive certain chemotherapy drugs, such as carboplatin and cisplatin because of an ongoing shortage. By October 2023, experts saw an improvement, although the “ongoing crisis” remained.  READ MORE: Patients With Lung Cancer Face Unmet Needs During Drug Shortages “We’re really proud of the work that we could do and achieve that through a critical drug shortage,” Tray said. “None of our patients missed a dose of chemotherapy and we were able to provide that for them.” Tray sat down with CURE® during the 49th Annual Oncology Nursing Society Annual Congress to discuss the ongoing chemo shortage and how patients and care teams approached these challenges. Transcript: Particularly at Hartford HealthCare, when we established this infrastructure, our goal was to make sure that every patient would get the treatment that they need and require, utilizing the data that we have from ASCO guidelines to ensure that we're getting the optimal high-quality standard of care in a timely fashion that we didn't have to delay therapies. So, we were able to do that by going down to the minutiae of the milligrams on hand, particularly when we had a lot of critical drug shortages. So it was really creating that process to really ensure that every patient would get the treatment that they needed. For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
Yuliya P.L Linhares, MD, an expert on CLL
Yuliya P.L Linhares, MD, and Josie Montegaard, MSN, AGPCNP-BC, experts on CLL
Image of a man with a beard.
Image of a man with gray facial hair and a navy blue suit with a light orange tie.
Image of a woman with black hair.
Related Content